Skip to main content

Table 4 Hierarchical linear model (HLM) of long-term relations of serum levels of BAFF and anti-Jo-1 antibodies with serum levels of CK, CRP, and disease activity

From: Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis

Predictors

ICCa

Explained variance (%)b

Intercept

Slopec

BAFF

anti-Jo-1

CK

BAFF (ng/ml)

p

anti- Jo-1 (kU/l)

p

CK (μkat/l)

p

BAFF (ng/ml)

p

anti- Jo-1 (kU/l)

p

CK (μkat/l)

p

Time from diagnosisd,e

0

62.3

31.2

1.85

˂ 0.001

340.9

0.04

9.06

0.04

0.01

0.10

11.9

0.21

−0.06

0.63

BAFFe (ng/ml)

0.030

79.1

49.6

748.0

0.03

0

0.99

91.6

0.22

4.34

0.003

anti-Jo-1e (kU/l)

0.678

31.6

72.3

2.33

˂ 0.001

1.4

0.34

0.002

0.03

0.02

0.05

CKe (μkat/l)

0.100

75.6

73.8

2.30

˂ 0.001

747.1

0.03

0.14

0.02

7.14

0.59

CRPf (mg/l)

0.107

74.3

70.2

44.1

2.35

˂ 0.001

749.5

0.03

8.7

0.02

0.15

0.08

− 21.7

0.76

0.98

0.07

Pulmonary VASg (mm)

0.582

61.7

60.4

ND

2.32

˂ 0.001

785.8

0.03

ND

0.11

0.16

−16.5

0.03

ND

Muscle VASg (mm)

0.319

84.5

71.9

ND

2.32

˂ 0.001

784.4

0.03

ND

−0.12

0.54

−7.8

0.22

ND

Global VASg (mm)

0.241

28.3

71.2

ND

1.30

˂ 0.001

939.3

0.07

ND

0.06

0.01

−7.4

0.21

ND

  1. Dependent variables are situated in columns and predictors in rows
  2. BAFF B-cell activating factor of the tumour necrosis factor family, CK creatine kinase, CRP C-reactive protein, ICC intra-class correlation coefficient, ND not done, VAS visual analogue scale
  3. aICC; the ratio of the between-individuals variance (level 2) to the total variance
  4. b% of variance explained at level 1 (within individuals): pseudo R2; based on HLM
  5. cAverage effect of explanatory variables (Slope) was estimated using maximum likelihood method with robust standard errors
  6. dAverage change over time (months from diagnosis); based on the unconditional growth model
  7. eDetermined in 80 repeated measures on 23 patients
  8. fDetermined in 79 repeated measures on 23 patients
  9. gDetermined in 73 repeated measures on 22 patients